Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

Total Voting Rights

6 Jan 2021 10:27

RNS Number : 7656K
Oncimmune Holdings PLC
06 January 2021
Β 

6 January 2021

Β 

Β 

Oncimmune Holdings plc

Β 

("Oncimmune" or the "Company")

Β 

Total Voting Rights

Β 

Β 

In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.

Β 

As at 31 December 2020, the Company's issued share capital was 63,662,446 ordinary shares of Β£0.01 each with voting rights. The Company does not hold any shares in treasury.

Β 

The above figure of 63,662,446 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Β 

Β 

Β 

For further information:

Β 

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk

Β 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

Β 

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

Β 

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Β 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TVREAEFKEAKFEFA
Date   Source Headline
4th May 202112:23 pmRNSTotal Voting Rights
8th Apr 20217:00 amRNSHolding(s) in Company
7th Apr 20212:05 pmRNSSecond Price Monitoring Extn
7th Apr 20212:00 pmRNSPrice Monitoring Extension
6th Apr 20211:48 pmRNSBlock Listing Six Monthly Return
6th Apr 20217:00 amRNSAgreements signed with Roche and Cedars-Sinai
6th Apr 20217:00 amRNSHolding(s) in Company
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20212:01 pmRNSResult of Oversubscribed Equity Placing
25th Mar 20217:45 amRNSLaunch of Equity Placing via Accelerated Bookbuild
15th Mar 20217:00 amRNSIssue of Equity and Total Voting Rights
1st Mar 20217:00 amRNSTotal Voting Rights
15th Feb 20217:00 amRNSInterim Results
25th Jan 20217:00 amRNSNotice of Half Year Results
19th Jan 20214:17 pmRNSDirectorate Change
18th Jan 202111:37 amRNSHolding(s) in Company
14th Jan 20219:49 amRNSPDMR Dealing
6th Jan 202110:27 amRNSTotal Voting Rights
18th Dec 20207:00 amRNSPDMR Dealing
15th Dec 20207:00 amRNSAutoantibody profiles publication for RA treatment
14th Dec 20207:00 amRNSEarlyCDT Lung blood test launch into the NHS
30th Nov 202011:21 amRNSResults of Annual General Meeting
11th Nov 20207:00 amRNSAgreement with Augmenta Bioworks
9th Nov 20207:00 amRNSNotice of AGM and Posting of Annual Report
30th Oct 20207:00 amRNSFull year results and progress update
28th Oct 20207:00 amRNSClinical study initiated by Biodesix in US
21st Oct 20207:00 amRNSAbstracts of Studies using EarlyCDT Lung
19th Oct 20208:21 amRNSReplacement: Notice of Full Year Results
19th Oct 20207:00 amRNSNotice of Full Year Results ended 31 May 2020
13th Oct 20207:00 amRNSAgreement with Cedars-Sinai to Profile COVID-19
8th Oct 202011:05 amRNSSecond Price Monitoring Extn
8th Oct 202011:00 amRNSPrice Monitoring Extension
6th Oct 20207:00 amRNSUK Government funding for tool for use in COVID-19
23rd Sep 20207:00 amRNSProfiling samples from Genentech
15th Sep 20202:00 pmRNSBlock Admission
11th Sep 202012:14 pmRNSNew Incentivisation Scheme for Senior Management
3rd Sep 20207:00 amRNSCost-effectiveness study assessing EarlyCDT Lung
2nd Sep 20207:00 amRNSAutoantibody profiling agreement signed
13th Aug 202011:38 amRNSExercise of Options and Total Voting Rights
12th Aug 20207:00 amRNSAppointment of Joint Brokers
10th Aug 20207:00 amRNSEarlyCDT Lung Blood Test Featured on ITV News
7th Aug 20207:00 amRNSExercise of Options and Total Voting Rights
5th Aug 20207:00 amRNSFurther evidence for the use of the EarlyCDT Lung
31st Jul 20207:00 amRNSERJ publishes results from the ECLS study
27th Jul 20207:00 amRNSRoche Contract Expansion to Profile Autoantibodies
24th Jul 20202:52 pmRNSExercise of Options and Total Voting Rights
8th Jul 20207:00 amRNSPaper highlights potential of ImmunoINSIGHTS in RA
1st Jul 20207:00 amRNSAuthorisation for EarlyCDT Lung in Brazil
30th Jun 20207:00 amRNSExercise of Options
9th Jun 20203:54 pmRNSGrant of Options and PDMR notification

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.